semaglutide gastrointestinal obstruction lawsuit in louisiana attorney Ozempic [May 2026 Update] The GLP-1 RA Legal Timeline:

Semaglutide (marketed under brand names Ozempic and Wegovy) was initially intended to help with diabetes management, but it has also been shown to help with weight loss, which in turn, can lower cardiovascular risk due to decreasing a persons Body Mass Index (BMI)

Pharmacy discount cards typically cannot be stacked with manufacturer savings offers

Several government organizations release guidelines to prevent, diagnose, and treat type 2 diabetes mellitus

the newer 7.2 mg dose approved in January 2026 produces around 20%

PlexusDx structures its flat monthly pricingstarting at $149 for compounded semaglutideto encourage consistent weekly use without the temptation to ration doses

These findings support the growing evidence that the established CV benefit of semaglutide is molecule-specific and cannot be generalized to the broader GLP-1 or GLP-1/GIP receptor agonist classes.